Effect of WR-1065 on 6-hydroxydopamine-induced catalepsy and IL-6 level in rats

Document Type : Original Article


1 Drug Applied Research Center, Department of Pharmacology and Toxicology, Tabriz University of Medical Sciences, Tabriz, Iran

2 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

3 Department of Pharmacology and Neurobiology Research Center, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran


Objective(s): Neuroinflammation and oxidative stress play a key role in pathogenesis of Parkinson’s disease (PD). In the present study we investigated the effect of reactive oxygen species (ROS) scavenger WR-1065 on catalepsy and cerebrospinal fluid (CSF) level of interleukin 6(IL-6) and striatum superoxide dismutase (SOD) activity  in 6-hydroxydopamine (6-OHDA) induced experimental model of PD.
Materials and Methods: Seventy two male Wistar rats were divided into 9 equal groups and 6-OHDA (8 μg/2 μl/rat) was infused unilaterally into substantia nigra pars copmacta (SNc) to induce PD. Catalepsy was measured by standard bar test, CSF level of IL-6 was assessed by enzyme-linked immunosorbent assay (ELISA) method and SOD activity measured by spectrophotometric method. In pre-treatment groups WR-1065 (20, 40 and 80 μg/2 μl/rat/day, for 3 days) was infused into the SNc before 6-OHDA administration and 21 days later, as a recovery period, behavioral and molecular assay tests were done.
Results: Our results showed that pre-treatment with WR-1065 improved (P<0.001) 6-OHDA-induced catalepsy in a dose dependent manner. In 6-OHDA-lesioned animals SOD activity in SNc and CSF level of IL-6 was decreased markedly (P<0.001) when compared with non-lesioned group, while pre-treatment with WR-1065(P<0.001) restored their levels up to the normal range.
Conclusion: Our study indicated that pre-treatment with WR-1065 could modulate catalepsy and IL-6 level in 6-OHDA-lesioned rats. Also WR1065 could increase SOD activity up to normal range. It can be regarded as an anti-oxidative drug in prevention or adjunctive therapy of PD.


1.Shadrina MI, Slominsky PA, Limborska SA. Molecular mechanisms of pathogenesis of Parkinson's disease. Int Rev Cell Mol Biol, 2010; 281:229-266.
2.Repetto MG. Free radicals, oxidative stress and oxidative damage in Parkinson's disease. 1st ed. Buenos Aires: INTECH Open Access Publisher; 2012.
3.Friedlich AL, Smith MA, Zhu X, Takeda A, Nunomura A, Moreira P, et al. Oxidative stress in Parkinson’s disease. Open Pathol J, 2009; 3:38-42.
4.Raha S, Robinson BH. Mitochondria, oxygen free radicals, and apoptosis. Am J Med Genet, 2001; 106:62-70.
5.Ciccone S, Maiani E, Bellusci G, Diederich M, Gonfloni S. Parkinson's disease: a complex interplay of mitochondrial DNA alterations and oxidative stress. Int J Mol Sci, 2013; 14:2388-2409.
6.Tufekci KU, Meuwissen R, Genc S, Genc K. Inflammation in Parkinson's disease. Adv Protein Chem Struct Biol, 2012; 88:69-132.
7.Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology, 2001; 40:959-975.
8.Haddadi R, Nayebi AM, Farajniya S, Brooshghalan SE, Sharifi H. Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: behavioral and molecular study. Daru, 2014; 22:38.
9.Bartels AL, Leenders KL. Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord, 2007; 22:1852-1856.
10. Closa D, Folch-Puy E. Oxygen free radicals and the systemic inflammatory response. IUBMB Life, 2004; 56:185-191.
11. Taylor JM, Main BS, Crack PJ. Neuro-inflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem Int, 2013; 62:803-819.
12. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta, 2011; 1813:878-888.
13. Sharifi H, Nayebi AM, Farajnia S, Haddadi R. Effect of chronic administration of buspirone and fluoxetine on inflammatory cytokines in 6-Hydroxydopamine-lesioned rats. Drug Res (Stuttg), 2015; 65:393-397.
14. Spooren A, Kolmus K, Laureys G, Clinckers R, De Keyser J, Haegeman G, et al. Interleukin-6, a mental cytokine. Brain Res Rev, 2011; 67:157-183.
15. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA, 2014; 311:1670-1683.
16. Calabresi P, Di Filippo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord, 2008; 23:570-579.
17. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord, 2007; 22:1379-1389.
18. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol, 2003; 53:61-70.
19. Chronidou F, Apostolakis E, Papapostolou I, Grintzalis K, Georgiou CD, Koletsis EN, et al. Beneficial effect of the oxygen free radical scavenger amifostine (WR-2721) on spinal cord ischemia/reperfusion injury in rabbits. J Cardiothorac Surg, 2009; 4:50.
20. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist, 2007; 12:738-747.
21. Nieder C, Andratschke NH, Wiedenmann N, Molls M. Prevention of radiation-induced central nervous system toxicity: a role for amifostine? Anticancer Res, 2004; 24:3803-3809.
22. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 3th ed. Amsterdam: Academic Press/Elsevier; 1997.
23. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys, 1984; 21:130-132.
24. Foolad F, Khodagholi F. Dietary supplementation with Salvia sahendica attenuates acetylcholinesterase activity and increases mitochondrial transcription factor A and antioxidant proteins in the hippocampus of amyloid beta-injected rats. J Pharm Pharmacol, 2013; 65:1555-1562.
25. Haddadi R, Brooshghalan SE, Farajniya S, Nayebi AM, Sharifi H. Short-Term Treatment with Silymarin Improved 6-OHDA-Induced Catalepsy and Motor Imbalance in Hemi-Parkisonian Rats. Adv Pharm Bull, 2015; in press.
26. Haddadi R, Mohajjel Nayebi A, Brooshghalan SE. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats. Neurosci Lett, 2013; 555:106-111.
27. Murley JS, Nantajit D, Baker KL, Kataoka Y, Li JJ, Grdina DJ. Maintenance of manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by repeated administration of the free thiol form of amifostine. Radiat Res, 2008; 169:495-505.